No FDA Class-Wide NAION Warning Exists for GLP-1 Agonists
Direct rebuttal of the specific Factum claim that the FDA imposed NAION warnings on GLP-1 drugs; the assertion has no supporting regulatory action.
The Factum headline claims the FDA mandated class-wide NAION warnings on all GLP-1 drugs after reviewing trial and real-world data. This is false. No such requirement has been issued. A 2024 JAMA Ophthalmology study found an association between semaglutide and NAION in diabetic patients but explicitly noted it does not prove causation and called for further research. Novo Nordisk has stated the data do not support a causal link, and the FDA's own adverse event database has not triggered a label change or class warning as of late 2024. Existing labels for Ozempic and Mounjaro address known risks like thyroid tumors and pancreatitis but contain no NAION language. European regulators have likewise issued no equivalent action.
Sources (1)
- [1]The Factum - full site digest(https://thefactum.ai)